Literature DB >> 8923105

The impact of social phobia on quality of life.

H U Wittchen1, E Beloch.   

Abstract

Although social phobia is a prevalent mental disorder in the general population, it has only recently received clinical and public attention and very few and rather general data are currently available on the general and disease-specific impairments, disabilities, handicaps and economic burdens associated with social phobia. This report summarizes findings from a case-control study in which quality of life and other indices of impairment in 65 subjects with social phobia but without significant comorbidity of other psychiatric disorders (pure social phobia) were compared to those in a matched control group of 65 subjects with a history of herpes infection. On the basis of the standardized Composite International Diagnostic Interview (CIDI, core version 1.1), the subjects with social phobia had been chronically impaired clinically for more than two decades, with an average duration of 22.9 years and an onset predominantly in childhood or adolescence. As assessed by the Social Functioning (SF-36) questionnaire, these subjects had a significantly lower quality of life, particularly in the scales measuring vitality, general health, mental health, role limitations due to emotional health and social functioning. Standardized summed scores for mental health components of the SF-36 showed that 23.1% of all the subjects with social phobia were severely impaired and 24.6% were significantly impaired compared to only 4.5% of control subjects impaired. Work productivity in the week before the study day, assessed by the Work Productivity And Impairment (WPAI) questionnaire, was significantly diminished in the subjects with social phobia, as indicated by (1) a threefold higher rate of unemployed cases, (2) a significantly elevated rate of mean work hours missed due to social phobia problems and (3) a significantly higher number of subjects reporting significant impairments in work performance. Slightly elevated rates of current (past 4 weeks) treatment by mental health specialists were found (9.2%) in the subjects with social phobia, and higher rates of lifetime psychotropic medication use (24.6%). Overall, these findings emphasize that social phobia is a chronic, impairing anxiety disorder, which results in considerable subjective suffering and has a long-term negative impact on work performance and social relationships. Current disabilities and impairments are usually less pronounced than in the past, presumably due to adaptive behaviors in the lifestyle of the respondents. Our data also suggest that social phobia is poorly recognized and treated by the health care and mental health system.

Entities:  

Mesh:

Year:  1996        PMID: 8923105     DOI: 10.1097/00004850-199606003-00004

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  28 in total

Review 1.  Unmasking social anxiety disorder.

Authors:  M B Stein; J M Gorman
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Validity and reliability of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire.

Authors:  A Rossi; P Rucci; M Mauri; G Maina; F Pieraccini; S Pallanti; J Endicott
Journal:  Qual Life Res       Date:  2005-12       Impact factor: 4.147

3.  Psychometric evaluation of social phobia and anxiety inventory for children (SPAI-C) and social anxiety scale for children-revised (SASC-R).

Authors:  Sanna Kuusikko; Kuusikko Sanna; Rachel Pollock-Wurman; Pollock-Wurman Rachel; Hanna Ebeling; Ebeling Hanna; Tuula Hurtig; Hurtig Tuula; Leena Joskitt; Joskitt Leena; Marja-Leena Mattila; Mattila Marja-Leena; Katja Jussila; Jussila Katja; Irma Moilanen; Moilanen Irma
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-09-19       Impact factor: 4.785

4.  Neurocircuitry underlying risk and resilience to social anxiety disorder.

Authors:  Jacqueline A Clauss; Suzanne N Avery; Ross M VanDerKlok; Baxter P Rogers; Ronald L Cowan; Margaret M Benningfield; Jennifer Urbano Blackford
Journal:  Depress Anxiety       Date:  2014-04-17       Impact factor: 6.505

5.  Affective and Self-Esteem Instability in the Daily Lives of People with Generalized Social Anxiety Disorder.

Authors:  Antonina S Farmer; Todd B Kashdan
Journal:  Clin Psychol Sci       Date:  2014-03-01

6.  Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: a meta-analysis.

Authors:  Stefan G Hofmann; Jade Q Wu; Hannah Boettcher
Journal:  J Consult Clin Psychol       Date:  2014-01-20

7.  Resting regional brain metabolism in social anxiety disorder and the effect of moclobemide therapy.

Authors:  Alex Doruyter; Patrick Dupont; Lian Taljaard; Dan J Stein; Christine Lochner; James M Warwick
Journal:  Metab Brain Dis       Date:  2017-11-03       Impact factor: 3.584

8.  A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder.

Authors:  J M Warwick; P Carey; G Van der Linden; C Prinsloo; D Niehaus; S Seedat; P Dupont; D J Stein
Journal:  Metab Brain Dis       Date:  2006-07-19       Impact factor: 3.584

9.  Post-traumatic stress disorder, social anxiety disorder, and depression in survivors of the Kosovo War: experiential avoidance as a contributor to distress and quality of life.

Authors:  Todd B Kashdan; Nexhmedin Morina; Stefan Priebe
Journal:  J Anxiety Disord       Date:  2008-07-01

Review 10.  A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective.

Authors:  Manishi Prasad; Peter Wahlqvist; Rich Shikiar; Ya-Chen Tina Shih
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.